晚期尿路上皮癌:影像学进展
本文综述晚期尿路上皮癌的基因组学进展与影像学作用,介绍不同治疗类别(联合化疗与免疫检查点抑制剂)的特异性疗效反应模式和不良事件,指出需要可靠的生物标志物(可能借助影像)预测预后和治疗反应,以选择最有效且毒性最小的治疗。
要点
- 晚期尿路上皮癌的影像表现和转移模式与肿瘤生物学相关。
- 联合化疗与免疫检查点抑制剂的疗效反应模式和不良事件各具治疗类别特异性。
- 研究结果指向需要可靠的生物标志物(可能借助影像)预测预后和治疗反应。
核心结论
- 研究结果指出需要可靠的生物标志物(可能借助影像)预测预后和对全身治疗的反应,并用于选择最有效治疗同时最小化毒性。
研究设计与样本
- 本文为综述,介绍晚期尿路上皮癌在遗传学分析、影像学当前作用、治疗反应及毒性的影像学表现以及未来潜在影像研究方向的最新进展。
关键影像表现/征象
- 影像学研究拓展了对晚期尿路上皮癌疾病表现、转移播散模式及其与尿路上皮癌基础生物学相关性的认识。
- 联合化疗方案和免疫检查点抑制剂各自导致治疗类别特异性的疗效反应模式和不良事件。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The recent genomic characterization of urothelial carcinoma by the Cancer Genome Atlas Project, made possible by the introduction of high throughput, reduced cost, and sequence analysis, has shed new insights on the biology of advanced disease. In addition, studies on imaging of advanced urothelial carcinoma have widened the knowledge on disease presentation and on pattern of metastatic spread and their correlation with the underlying biology of urothelial carcinoma. The wide range of treatments for advanced urothelial cancer, including combined chemotherapy regimens and immune checkpoint inhibitors, each result in treatment class-specific patterns of response and adverse events. Results of studies point to the need for a reliable biomarker, perhaps with imaging, that predicts prognosis and treatment response to systemic treatment, and can be used to select the most effective treatment while minimizing toxicity. This review of advanced urothelial cancer introduces the latest advances in genetic profiling, the current role of imaging, the radiographic appearance of treatment response and their toxicities, and details potential future areas of imaging research.
引用
- Alessandrino F, Ghaith O, Williams K, et al. Advanced urothelial cancer: a radiology update. Abdom Radiol (NY). 2019. PMID: 31363813. doi:10.1007/s00261-019-02148-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。